These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1529 related items for PubMed ID: 10896249

  • 1. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 2. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L.
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [Abstract] [Full Text] [Related]

  • 3. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ, Murphy RT, Dooley M, Foley JB, Fitzgerald DJ.
    J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
    [Abstract] [Full Text] [Related]

  • 4. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF.
    J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
    [Abstract] [Full Text] [Related]

  • 5. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A, Voss R.
    Thromb Res; 2006 Dec; 117(3):307-14. PubMed ID: 15894353
    [Abstract] [Full Text] [Related]

  • 6. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM, Buckland RJ, Holgate CE, Storey RF.
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [Abstract] [Full Text] [Related]

  • 7. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A.
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [Abstract] [Full Text] [Related]

  • 8. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
    Marciniak SJ, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL.
    Thromb Haemost; 2002 Jun; 87(6):1020-5. PubMed ID: 12083481
    [Abstract] [Full Text] [Related]

  • 9. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ, Taatjes DJ, Sobel BE.
    Cardiovasc Res; 2000 Jan 14; 45(2):437-46. PubMed ID: 10728364
    [Abstract] [Full Text] [Related]

  • 10. Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.
    Weber AA, Schrör K.
    Blood; 2001 Sep 01; 98(5):1619-21. PubMed ID: 11520817
    [Abstract] [Full Text] [Related]

  • 11. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G, Hafner T, Siller-Matula JM, Francesconi M, Grohs K, Wilhelm E, Podczeck-Schweighofer A.
    Thromb Res; 2013 Jul 01; 132(1):e36-41. PubMed ID: 23791395
    [Abstract] [Full Text] [Related]

  • 12. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
    Chakrabarti S, Clutton P, Varghese S, Cox D, Mascelli MA, Freedman JE.
    Thromb Res; 2004 Jul 01; 113(3-4):225-33. PubMed ID: 15140587
    [Abstract] [Full Text] [Related]

  • 13. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
    Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D.
    Circulation; 1999 May 04; 99(17):2231-8. PubMed ID: 10226086
    [Abstract] [Full Text] [Related]

  • 14. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
    Keating FK, Whitaker DA, Sobel BE, Schneider DJ.
    Thromb Res; 2004 May 04; 113(1):27-34. PubMed ID: 15081562
    [Abstract] [Full Text] [Related]

  • 15. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
    Abernethy DR, Pezzullo J, Mascelli MA, Frederick B, Kleiman NS, Freedman J.
    Clin Pharmacol Ther; 2002 Mar 04; 71(3):186-95. PubMed ID: 11907493
    [Abstract] [Full Text] [Related]

  • 16. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model.
    Klinkhardt U, Graff J, Harder S.
    Clin Pharmacol Ther; 2002 Mar 04; 71(3):176-85. PubMed ID: 11907492
    [Abstract] [Full Text] [Related]

  • 17. In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia.
    Mak KH, Kottke-Marchant K, Brooks LM, Topol EJ.
    Thromb Haemost; 1998 Dec 04; 80(6):989-93. PubMed ID: 9869172
    [Abstract] [Full Text] [Related]

  • 18. Platelet glycoprotein IIb/IIIa receptor antagonist (abciximab) inhibited platelet activation and promoted skin flap survival after ischemia/reperfusion injury.
    Kuo YR, Jeng SF, Wang FS, Huang HC, Wei FC, Yang KD.
    J Surg Res; 2002 Sep 04; 107(1):50-5. PubMed ID: 12384064
    [Abstract] [Full Text] [Related]

  • 19. Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.
    Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S.
    Clin Pharmacol Ther; 2000 Mar 04; 67(3):305-13. PubMed ID: 10741635
    [Abstract] [Full Text] [Related]

  • 20. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression.
    Steiner S, Seidinger D, Huber K, Kaun C, Minar E, Kopp CW.
    Arterioscler Thromb Vasc Biol; 2003 Sep 01; 23(9):1697-702. PubMed ID: 12869353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 77.